Table 2.
Cohort characteristics and immunohistochemical distribution of somatostatin receptor expression (ANOVA)
| SSTR1 | SSTR2A | SSTR3 | SSTR4 | SSTR5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value | Mean (95%CI) | p Value | |
| Gender | |||||||||||
| Female | 502 (69.1) | 6.7 (6.4–6.9) | 0.0269* | 5.8 (5.5–6.0) | 0.2076 | 2.2 (2.0–2.4) | 0.4467 | 2.8 (2.7–3.0) | 0.0806 | 4.8 (4.7–5.0) | 0.9765 |
| Male | 224 (30.9) | 6.2 (5.8–6.5) | 6.0 (5.7–6.4) | 2.3 (2.0–2.6) | 2.6 (2.4–2.8) | 4.8 (4.6–5.1) | |||||
| Age (cutoff according to CART) | 41.91 years | 34.47 years | 72.45 years | 42.98 years | 45.77 years | ||||||
| ≥ | 6.7 (6.5–6.9) | < .0001* | 5.9 (5.7–6.1) | 0.0011* | 1.4 (1.0–1.8) | < .0001* | 2.6 (2.5–2.8) | 0.0005* | 5.0 (4.8–5.1) | 0.0002* | |
| < | 5.5 (5.0–6.0) | 4.7 (4.0–5.4) | 2.4 (2.2–3.6) | 3.2 (2.9–3.5) | 4.3 (4.1–4.6) | ||||||
| Recurrence | |||||||||||
| Primary | 613 (84.4) | 6.7 (6.5–6.9) | < .0001* | 5.8 (5.6–6.0) | 0.3696 | 2.2 (2.0–2.3) | 0.3610 | 2.8 (2.6–2.9) | 0.2436 | 4.9 (4.7–5.0) | 0.1503 |
| Recurrence | 113 (15.6) | 5.5 (5.0–6.0) | 6.1 (5.6–6.5) | 2.4 (2.0–2.8) | 2.6 (2.3–2.9) | 4.6 (4.2–4.9) | |||||
| Prior radiation | |||||||||||
| Yes | 61 (8.4) | 5.4 (4.7–6.1) | 0.0007* | 6.1 (5.4–6.8) | 0.4835 | 2.1 (1.5–2.6) | 0.6414 | 2.4 (2.0–2.9) | 0.1291 | 4.3 (3.9–4.8) | 0.0340* |
| No | 665 (91.6) | 6.6 (6.4–6.8) | 5.8 (5.6–6.0) | 2.2 (2.1–2.4) | 2.8 (2.7–2.9) | 4.9 (4.7–5.0) | |||||
| NF2 | |||||||||||
| Yes | 73 (10.1) | 4.6 (4.0–5.2) | < .0001* | 5.0 (4.4–5.6) | 0.0049* | 3.8 (3.3–4.3) | < .0001* | 3.6 (3.3–4.0) | < .0001* | 3.9 (3.5–4.3) | < .0001* |
| No | 653 (90.0) | 6.7 (6.5–6.9) | 6.0 (5.8–6.2) | 2.0 (1.9–2.2) | 2.6 (2.5–2.8) | 5.0 (4.8–5.1) | |||||
| Localization | |||||||||||
| Convexity/Falx | 282 (38.8) | 5.8 (5.5–6.2) | < .0001* | 5.6 (5.3–5.9) | 0.0003* | 1.7 (1.5–2.0) | < .0001* | 2.6 (2.4–2.8) | 0.0062* | 4.5 (4.3–4.7) | < .0001* |
| Skull base | 375 (51.7) | 6.7 (6.5–7.0) | 6.2 (5.9–6.5) | 2.6 (2.4–2.9) | 2.8 (2.6–2.9) | 4.9 (4.7–5.1) | |||||
| Spinal | 69 (9.5) | 8.1 (7.5–8.8) | 4.9 (4.3–5.6) | 1.7 (1.2–2.2) | 3.3 (2.9–3.7) | 5.7 (5.2–6.1) | |||||
| 2016 WHO classification | |||||||||||
| I | 585 (80.6) | 6.8 (6.6–7.0) | < .0001* | 5.8 (5.5–6.0) | 0.0160* | 2.2 (2.0–2.4) | 0.8841 | 2.9 (2.7–3.0) | 0.0011* | 4.9 (4.7–5.0) | 0.0003* |
| II | 118 (16.3) | 5.6 (5.1–6.1) | 6.5 (6.0–7.0) | 2.2 (1.8–2.6) | 2.4 (2.1–2.7) | 4.8 (4.4–5.1) | |||||
| III | 23 (3.2) | 4.6 (3.5–5.8) | 5.5 (4.4–6.5) | 2.0 (1.1–2.9) | 2.0 (1.3–2.6) | 3.3 (2.5–4.1) | |||||
Abbreviations: SSTR somatostatin receptor, CI confidence interval, CART classification and regression tree, NF2 neurofibromatosis type 2, WHO World Health Organization, ANOVA analysis of variance; asterisk (*) presents statistically significant results